AF Association News & Events
WORLD HEART RHYTHM WEEK 5-11 JUNE 2017 TAKE THE PULSE CHECK CHALLENGE – IT COULD SAVE YOUR LIFE
HIGH RISK AF PATIENTS DENIED ACCESS TO LIFE-SAVING TREATMENT
Heart For Heart Initiative Launched To Improve Smartphone Performance of Arrhythmia Detection
Happitech, Arrhythmia Alliance and Bug Labs will announce the launch of the Heart for Heart e-health initiative. This initiative invites people to participate in the world’s largest crowdsourced heart health initiative by inviting them to contribute their heart rhythm data using the free Heart for Heart iPhone App. “In the same way, you donate your money for a good cause, we are asking you to donate 90 seconds of your heart rhythm data to help advance research,” said Yosef Safi Harb, Founder of Happitech. “The data generated by Heart for Heart will be used to better differentiate between AF and a regular heartbeat rhythm. This will speed up the development and accuracy of the technology and create insights into new health correlations.”
Bluffton installs first public-use AED at local park
The Town of Bluffton has installed its first public-use automated external defibrillator (AED) in DuBois Park Tuesday as a part of its #BlufftonHeartsMatter campaign.
Public access defibrillator in Dubois Park, Bluffton
Tuesday, the town of Bluffton celebrated a new public AED placement that is going to save lives. Joined by the Arrhythmia Alliance, town leaders and ...
New patient survey results show 80% of AF patients say ‘YES’ to the freedom that INR self-monitoring gives them
The purpose of this survey was to help discover patient thoughts and opinions about INR self-monitoring versus clinic visits. Several trials have demonstrated that patient self-monitoring (PSM) by those on long term warfarin significantly improves time in therapeutic range (TTR) and leads to better management outcomes.
Arrhythmia Alliance places 3000th Public Access Defibrillator on World Restart the Heart Day
“AEDs must be as commonplace as fire extinguishers and smoke alarms if we are to dramatically reduce the number of deaths from sudden cardiac arrest in the UK.”
ARRHYTHMIA ALLIANCE PLACES 3000TH PUBLIC ACCESS DEFIBRILLATOR ON WORLD RE-START THE HEART DAY
New real-world analysis reports lower risk of major bleeding with dabigatran compared to rivaroxaban in stroke prevention
Ingelheim, Germany, 13.October 2016 – A large observational study by researchers from the U.S. FDA has found that dabigatran (150 mg twice daily) was associated with lower rates of intracranial haemorrhage and major extracranial bleeding, including major gastrointestinal bleeding than rivaroxaban (20 mg once daily) in patients with atrial fibrillation (AF). The study is the largest observational study to-date comparing the two drugs, and analysed data from over 118,000 AF patients. Based on the data published in JAMA Internal Medicine, the accompanying Editor’s Note written by Parks and Redberg suggests that physicians should “prescribe dabigatran over rivaroxaban for patients with atrial fibrillation.”
HEART RHYTHM CONGRESS DEBATES NEED FOR SCREENING OF UNKNOWN OR UNDIAGNOSED ATRIAL FIBRILLATION (AF)
Thursday 13 October, Heart Rhythm Congress, Birmingham, UK: Many of the world’s leading authorities on the management and treatment of atrial fibrillation (AF) met at the Heart Rhythm Congress to debate the latest evidence supporting the value of screening for people with unknown AF.